Reports
Sale
North America Multiplexed Diagnostics Market Size, Share: By Product Type: Reagents & Consumables, Instruments, Others; By Technology: Low Density Multiplexed Assays, Medium Density Multiplexed Assays, High Density Multiplexed Assays, Others; By Application; By End User; Regional Analysis; Supplier Landscape; 2024-2032
North America Multiplexed Diagnostics Market Outlook
The global multiplexed diagnostics market size was valued at USD 12.9 billion in 2023, with North America holding a substantial market share. The market is driven by the advancements in multiplexing technologies. It is expected to grow at a CAGR of 15.2% during the forecast period of 2024-2032, with the values likely to attain USD 46.2 billion by 2032.
Key Takeaways
- Nearly half of Americans have some type of heart disease and 1 in 5 deaths in the United States are caused by heart disease annually. Multiplexed diagnostics can be used to attain actionable health insights for cardiovascular disease patients in less time and cost.
- The introduction of technologically advanced multiplexed diagnostic platforms is assisting clinicians in delivering rapid treatment to patients, which is likely to boost the North America multiplexed diagnostics market share. In February 2024, PathogenDx, launched D3 Array™-UTI, a multiplexed molecular diagnostic technology based on PathogenDx's patented Dynamic Dimensional Detection (D3 Array™) to quickly detect urinary tract infection and antibiotic resistance.
- One of the major market trends is the increased funding from government organizations to advance diagnostic technologies. In April 2023, Sapphiros AI Bio received USD 11.1 million from a National Institutes of Health (NIH) initiative to develop an over the counter (OTC) multiplex molecular respiratory diagnostic test.
North America Multiplexed Diagnostics Market Analysis
Multiplexing is characterized by the simultaneous detection or identification of multiple biomarkers in a single diagnostic test. Multiplexed detection of biomarkers in certain diseases helps in accurately diagnosing the patient, as well as selecting the appropriate therapy. Thus, multiplexed diagnostic methods improve patient outcomes along with decreasing associated healthcare costs. Further, advancements in these techniques have led to increased efficiency and output, resulting in higher adoption in clinical laboratories and boosting North America multiplexed diagnostics market growth.
The rise in chronic disease burden including cardiovascular diseases and cancer positively impacts the market size. Recent data suggests that nearly half of Americans have some type of heart disease . Moreover, 1 in 5 deaths in the United States are caused by a heart disease annually. Multiplexed diagnostics can prove to be valuable in getting actionable health insights for cardiovascular disease patients in lesser time and cost. The multiplex detection of relevant biomarkers can not only reveal the pathophysiology of the disease but also help in picking the most effective treatment plan, thereby, propelling the North America multiplexed diagnostics market demand.
In April 2023, Sapphiros AI Bio, a United States-based computational biology company announced its selection in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program, receiving USD 11.1 million as part of the NIH initiative to develop an over the counter (OTC) multiplex molecular respiratory diagnostic test. The firm intends to use the funds to design an easy-to-use, affordable, and rapidly deployable diagnostic method for the detection of influenza A, influenza B, respiratory syncytial virus (RSV), and COVID-19 in a single test. The increased investment from various sectors to advance diagnostic technologies, particularly government initiatives that offer robust financial aid, are expected to augment North America multiplexed diagnostics market share.
In February 2024, PathogenDx, a next-generation microarray technology provider based in Arizona, United States, launched D3 Array™-UTI, a multiplexed molecular diagnostic technology based on PathogenDx’s patented Dynamic Dimensional Detection (D3 Array™) to detect urinary tract infection and antibiotic resistance. The multiplexed PCR test, with automated data analysis and reporting, can detect 26 pathogens and 12 antibiotic resistance gene markers, thereby advancing UTI diagnosis, and improving patient outcomes. The introduction of such technologically advanced multiplexed diagnostic platforms that can assist clinicians in delivering rapid treatment to patients is poised to significantly elevate the market value in the forecast period.
North America Multiplexed Diagnostics Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product Type | Reagents & Consumables, Instruments, Others |
| Technology | Low Density Multiplexed Assays, Medium Density Multiplexed Assays, High Density Multiplexed Assays, Very High-Density Multiplexed assays, Next-Generation Sequencing Assays, Others |
| Application | Disease Diagnostics, Drug Development, Molecular Diagnostics, Others |
| End User | Hospitals, Clinical Laboratories, Academic & Research Institutes, Diagnostics Centers, Others |
| Countries | United States of America, Canada |
North America Multiplexed Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- Agilent Technologies
- BioMerieux SA
- Bio-Rad Laboratories
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Qiagen N.V.
- Siemens Healthineers
- Luminex Corporation
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Multiplexed Diagnostics Market Overview
3.1 North America Multiplexed Diagnostics Market Historical Value (2017-2023)
3.2 North America Multiplexed Diagnostics Market Forecast Value (2024-2032)
4 North America Multiplexed Diagnostics Market Landscape*
4.1 North America Multiplexed Diagnostics Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Multiplexed Diagnostics Market: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
5 North America Multiplexed Diagnostics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Multiplexed Diagnostics Market Segmentation (2017-2032)
6.1 North America Multiplexed Diagnostics Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Reagents & Consumables
6.1.3 Instruments
6.1.4 Others
6.2 North America Multiplexed Diagnostics Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Low Density Multiplexed Assays
6.2.3 Medium Density Multiplexed Assays
6.2.4 High Density Multiplexed Assays
6.2.5 Very High-Density Multiplexed assays
6.2.6 Next-Generation Sequencing Assays
6.2.7 Others
6.3 North America Multiplexed Diagnostics Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Disease Diagnostics
6.3.3 Drug Development
6.3.4 Molecular Diagnostics
6.3.5 Others
6.4 North America Multiplexed Diagnostics Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Clinical Laboratories
6.4.4 Academic & Research Institutes
6.4.5 Diagnostics Centers
6.4.6 Others
6.5 North America Multiplexed Diagnostics Market (2017-2032) by Countries
6.5.1 Market Overview
6.5.2 United States of America
6.5.3 Canada
7 United States of America Multiplexed Diagnostics Market (2017-2032)
7.1 United States of America Multiplexed Diagnostics Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Reagents & Consumables
7.1.3 Instruments
7.1.4 Others
7.2 United States of America Multiplexed Diagnostics Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Low Density Multiplexed Assays
7.2.3 Medium Density Multiplexed Assays
7.2.4 High Density Multiplexed Assays
7.2.5 Very High-Density Multiplexed assays
7.2.6 Next-Generation Sequencing Assays
7.2.7 Others
7.3 United States of America Multiplexed Diagnostics Market (2017-2032) by Application
7.3.1 Market Overview
7.3.2 Disease Diagnostics
7.3.3 Drug Development
7.3.4 Molecular Diagnostics
7.3.5 Others
7.4 United States of America Multiplexed Diagnostics Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals
7.4.3 Clinical Laboratories
7.4.4 Academic & Research Institutes
7.4.5 Diagnostics Centers
7.4.6 Others
8 Canada Multiplexed Diagnostics Market (2017-2032)
8.1 Canada Multiplexed Diagnostics Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Reagents & Consumables
8.1.3 Instruments
8.1.4 Others
8.2 Canada Multiplexed Diagnostics Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Low Density Multiplexed Assays
8.2.3 Medium Density Multiplexed Assays
8.2.4 High Density Multiplexed Assays
8.2.5 Very High-Density Multiplexed assays
8.2.6 Next-Generation Sequencing Assays
8.2.7 Others
8.3 Canada Multiplexed Diagnostics Market (2017-2032) by Application
8.3.1 Market Overview
8.3.2 Disease Diagnostics
8.3.3 Drug Development
8.3.4 Molecular Diagnostics
8.3.5 Others
8.4 Canada Multiplexed Diagnostics Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals
8.4.3 Clinical Laboratories
8.4.4 Academic & Research Institutes
8.4.5 Diagnostics Centers
8.4.6 Others
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Thermo Fisher Scientific Inc.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Agilent Technologies
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 BioMerieux SA
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Bio-Rad Laboratories
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Illumina, Inc.
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 F. Hoffmann-La Roche Ltd.
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Hologic, Inc.
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Qiagen N.V
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Siemens Healthineers
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Luminex Corporation
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Multiplexed Diagnostics Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The North America multiplexed diagnostics market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 15.2% during the forecast period of 2024-2032 and is likely to reach a market value of USD 46.2 billion by 2032.
Technological advancements in the multiplexed diagnostics platforms are fuelling the demand for the market.
One of the significant trends in the market is increased funding from government organizations to advance diagnostic technologies. In April 2023, Sapphiros AI Bio received USD 11.1 million from a National Institutes of Health (NIH) initiative, intended to develop an over the counter (OTC) multiplex molecular respiratory diagnostic test.
Based on the product type, the market is segmented into reagents, consumables, and instruments, among others.
Technologies available in the market include low density multiplexed assays, medium density multiplexed assays, high density multiplexed assays, very high-density multiplexed assays, and next-generation sequencing assays, among others.
End users of the market are hospitals, clinical laboratories, academic and research institutes, and diagnostics centers, among others.
Major applications of multiplexed diagnostics include disease diagnostics, drug development, and molecular diagnostics, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Thermo Fisher Scientific Inc., Agilent Technologies, BioMerieux SA, Bio-Rad Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers, and Luminex Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER